SG11201908475RA - Process for making hepatitis b core protein modulators - Google Patents
Process for making hepatitis b core protein modulatorsInfo
- Publication number
- SG11201908475RA SG11201908475RA SG11201908475RA SG11201908475RA SG 11201908475R A SG11201908475R A SG 11201908475RA SG 11201908475R A SG11201908475R A SG 11201908475RA SG 11201908475R A SG11201908475R A SG 11201908475RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- pct
- hepatitis
- carmel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762470560P | 2017-03-13 | 2017-03-13 | |
| PCT/US2018/022100 WO2018169907A1 (en) | 2017-03-13 | 2018-03-13 | Process for making hepatitis b core protein modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908475RA true SG11201908475RA (en) | 2019-10-30 |
Family
ID=61768549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908475R SG11201908475RA (en) | 2017-03-13 | 2018-03-13 | Process for making hepatitis b core protein modulators |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11040965B2 (https=) |
| EP (1) | EP3596070A1 (https=) |
| JP (1) | JP7179751B2 (https=) |
| KR (1) | KR102575605B1 (https=) |
| CN (1) | CN110612300B (https=) |
| AU (1) | AU2018236188B2 (https=) |
| CA (1) | CA3056696A1 (https=) |
| SG (1) | SG11201908475RA (https=) |
| WO (1) | WO2018169907A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017326356A1 (en) | 2016-09-15 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
| SG11201908012SA (en) | 2017-03-02 | 2019-09-27 | Assembly Biosciences Inc | Cyclic sulfamide compounds and methods of using same |
| SG11202112590WA (en) * | 2019-05-24 | 2021-12-30 | Assembly Biosciences Inc | Pharmaceutical compositions for the treatment of hbv |
| CN111333513B (zh) * | 2020-04-17 | 2021-08-27 | 江苏恒沛药物科技有限公司 | 一种2,4-二氟-3-硝基苯甲酸的制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1480553A (en) | 1976-06-03 | 1977-07-20 | Pfizer Ltd | Tricyclic sulphonamides |
| JPS58225074A (ja) | 1982-06-25 | 1983-12-27 | Chugai Pharmaceut Co Ltd | ジベンゾオキサゼピン誘導体 |
| GB9109557D0 (en) | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB9707695D0 (en) * | 1996-08-07 | 1997-06-04 | Hoffmann La Roche | Tricyclic dione derivatives |
| US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| DE102004004928A1 (de) | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
| CA2625423A1 (en) | 2005-10-17 | 2007-04-26 | Acadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
| US20070105835A1 (en) | 2005-11-07 | 2007-05-10 | Kazantsev Aleksey G | Compositions and methods for modulating poly(ADP-ribose) polymerase activity |
| JP4042065B1 (ja) | 2006-03-10 | 2008-02-06 | 健治 吉田 | 情報処理装置への入力処理システム |
| WO2008036139A2 (en) | 2006-06-07 | 2008-03-27 | The Regents Of The University Of California | Inhibitors of mshc and homologs thereof, and methods of identifying same |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| CN102164605A (zh) | 2008-07-23 | 2011-08-24 | 美国卫生和人力服务部 | 用作抗疟药的疟原虫表面阴离子通道抑制剂 |
| WO2012045194A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| EP3085368A1 (en) | 2011-07-01 | 2016-10-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| US20150141384A1 (en) * | 2012-07-03 | 2015-05-21 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
| RU2519546C1 (ru) | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2015017412A1 (en) | 2013-07-29 | 2015-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists |
| CN104803880B (zh) * | 2014-01-23 | 2017-11-21 | 广州喜鹊医药有限公司 | 一种具有神经保护作用的化合物及其制备方法和应用 |
| PT3116316T (pt) | 2014-03-13 | 2019-09-30 | Assembly Biosciences Inc | Moduladores alostéricos da proteína do núcleo da hepatite b |
| WO2015189035A1 (en) | 2014-06-10 | 2015-12-17 | Basf Se | Substituted [1,2,4]triazole and imidazole compounds as fungicides |
| TWI730985B (zh) | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| AU2017326356A1 (en) * | 2016-09-15 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
-
2018
- 2018-03-13 EP EP18713555.3A patent/EP3596070A1/en not_active Withdrawn
- 2018-03-13 AU AU2018236188A patent/AU2018236188B2/en not_active Ceased
- 2018-03-13 KR KR1020197029525A patent/KR102575605B1/ko active Active
- 2018-03-13 WO PCT/US2018/022100 patent/WO2018169907A1/en not_active Ceased
- 2018-03-13 CN CN201880030078.4A patent/CN110612300B/zh not_active Expired - Fee Related
- 2018-03-13 JP JP2019550235A patent/JP7179751B2/ja active Active
- 2018-03-13 CA CA3056696A patent/CA3056696A1/en active Pending
- 2018-03-13 US US16/493,614 patent/US11040965B2/en not_active Expired - Fee Related
- 2018-03-13 SG SG11201908475R patent/SG11201908475RA/en unknown
-
2021
- 2021-01-14 US US17/149,485 patent/US20210380577A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11040965B2 (en) | 2021-06-22 |
| AU2018236188B2 (en) | 2022-01-27 |
| CN110612300A (zh) | 2019-12-24 |
| CA3056696A1 (en) | 2019-09-20 |
| WO2018169907A1 (en) | 2018-09-20 |
| AU2018236188A1 (en) | 2019-10-17 |
| US20210380577A1 (en) | 2021-12-09 |
| CN110612300B (zh) | 2023-10-20 |
| KR20190128675A (ko) | 2019-11-18 |
| JP7179751B2 (ja) | 2022-11-29 |
| JP2020510059A (ja) | 2020-04-02 |
| EP3596070A1 (en) | 2020-01-22 |
| KR102575605B1 (ko) | 2023-09-05 |
| US20200002325A1 (en) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901959YA (en) | Modified stem cell memory t cells, methods of making and methods of using same | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201908012SA (en) | Cyclic sulfamide compounds and methods of using same | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201810522UA (en) | Anti-cd40 antibodies and their uses | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201908475RA (en) | Process for making hepatitis b core protein modulators | |
| SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
| SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof |